GlassScriptPhysician profile
Marko Stephen Tkach
NPI 1386252310
$7,340.22
in general payments reported to CMS, 2019-2025
36 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $245 · 2021: $826 · 2022: $1,838 · 2023: $2,053 · 2024: $1,299 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,431.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,035.62 | 2020-2024 | Farxiga, Breztri, Lokelma |
| Amgen INC. | $861.95 | 2021-2025 | Tepezza, Otezla, Evenity |
| Abbott Laboratories | $649.43 | 2023-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $499.74 | 2020-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $455.38 | 2022-2025 | |
| Novo Nordisk INC | $417.77 | 2021-2025 | Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $322.12 | 2024-2025 | |
| Corcept Therapeutics | $257.40 | 2021-2024 | Korlym |
| Avanir Pharmaceuticals, INC. | $244.77 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $237.76 | 2022-2023 | Austedo |
| Glaxosmithkline, LLC. | $223.22 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $215.14 | 2022-2023 | Pomalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.13 | 2022-2025 | Jardiance |
| Alkermes, INC. | $193.11 | 2023-2024 | Lybalvi |
| Kyowa Kirin, INC. | $159.84 | 2024-2025 | Crysvita |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marko Tkach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.